Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
Identification of a novel human cellular HDL biosynthesis defect
European Heart Journal, 06/30/09
Rashid S et al. – Results indicate for the first time in humans that phospholipid and cholesterol efflux are 2 separate and distinct processes in cellular high-density lipoprotein (HDL) biosynthesis and that normal cellular phospholipid efflux is necessary for formation of larger {alpha}-HDL particles. Defective ABCA1 protein regulation results in a defect in phospholipid efflux, treatable with physiological oxysterols, a current therapeutic target that may serve to raise HDL levels in severe HDL deficiencies, pending further study.
Methods- Study of the cellular basis of a novel HDL-deficiency phenotype
- Screen of 54 subjects of French Canadian ancestry with severe HDL deficiency
- Exclusion of pts with mutations in genes currently associated with low HDL (ABCA1, LCAT, APOA-I, and SMPD1)
- Cellular phospholipid efflux impaired in HDL biosynthesis process but cholesterol efflux normal in 2 pts
- On 2-dimensional gel electrophoresis analysis, the 2 impaired phospholipid efflux pts primarily defective in larger {alpha}-HDL subpopulations
- In fibroblasts from affected subjects, oxysterol stimulation resulted in increased ABCA1 protein expression and normalized defective phospholipid efflux defect
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia
Journal of Clinical Lipidology, 10/14/09
Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease
The American Journal of Cardiology, 10/21/09
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
Vascular Health and Risk Management, 09/22/09
Today in Basic Science/Genetics...keeping you current
Receive free subspecialty "5-minute updates" via email
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
The Lancet, 10/27/09
Obesity-Related Cardiorenal Syndrome
The Journal of Clinical Hypertension, 10/20/09
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis
Arthritis Care and Research , 11/03/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


